Weinstein, C., Jordan, K., Green, S., Khanani, S., Beckford-Brathwaite, E., Vallejos, W., . . . Rapoport, B. L. (2020). Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: A subgroup analysis from a randomized clinical trial of response in subjects by cancer type. BMC cancer, 20(1), 918-10. https://doi.org/10.1186/s12885-020-07259-5
Citácia podle Chicago (17th ed.)Weinstein, Cindy, Karin Jordan, Stuart Green, Saleem Khanani, Elizabeth Beckford-Brathwaite, Waldimir Vallejos, Annpey Pong, Stephen J. Noga, a Bernardo L. Rapoport. "Single-dose Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy Regimens: A Subgroup Analysis from a Randomized Clinical Trial of Response in Subjects by Cancer Type." BMC Cancer 20, no. 1 (2020): 918-10. https://doi.org/10.1186/s12885-020-07259-5.
Citácia podľa MLA (8th ed.)Weinstein, Cindy, et al. "Single-dose Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy Regimens: A Subgroup Analysis from a Randomized Clinical Trial of Response in Subjects by Cancer Type." BMC Cancer, vol. 20, no. 1, 2020, pp. 918-10, https://doi.org/10.1186/s12885-020-07259-5.